# US 2010/0306862 A1 · Non-human animal model for frontotemporal lobar degeneration with ubiquitin-positive inclusions (ftld-u)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0306862 A1
- Document ID: US20100306862A1
- Status: Published application
- Kind: A1
- Application number: 12/785,653
- Filed: 2010-05-24
- Published: 2010-12-02
- Earliest claimed: 2009-06-02
- Assignees: Academia Sinica
- Inventors: CHE-KUN JAMES SHEN; KUEN-JER TSAI
- Web page: https://patentgrep.com/patent/US20100306862A1

## CPC

- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- C12N 5/0618: {Cells of the nervous system}
- A01K 2217/052: inducing gain of function
- A01K 2217/206: Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
- A01K 2227/105: Murine
- A01K 2267/0356: Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Non-human animal models for frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) are disclosed. The invention relates to a transgenic mouse whose genome comprises a transgene operably linked to a neuronal specific promoter effective for an increased expression of the transgene in the brain of the mouse, in which the transgene comprises a nucleotide sequence encoding TAR DNA-binding protein 43 (TDP-43). The transgenic mouse exhibits reduced or impaired learning and memory capacity, and may further exhibits progressively impaired or reduced motor functions. Methods of using such animal models are also disclosed.

## Claims

### Claim 1

A transgenic mouse whose genome comprises a transgene operably linked to a neuronal specific promoter effective for an increased expression of the transgene in the brain of the mouse, the transgene comprising a nucleotide sequence encoding TAR DNA-binding protein 43 (TDP-43), wherein the mouse exhibits an increased expression of TDP-43 in the brain thereof.

### Claim 2 (depends on 1)

The transgenic mouse of claim 1, wherein the neuronal specific promoter is selected from the group consisting of Ca2+/calmodulin-dependent kinaseIIα (CaMKIIα) promoter, neuron-specific enolase (NSE) promoter and motor neuron-specific gene Hb9 promoter.

### Claim 3 (depends on 1)

The transgenic mouse of claim 1, wherein the neuronal specific promoter is Ca2+/calmodulin-dependent kinaseIIα (CaMKIIα) promoter.

### Claim 4 (depends on 3)

The transgenic mouse of claim 3, wherein the mouse exhibits reduced or impaired learning and memory capacity.

### Claim 5 (depends on 4)

The transgenic mouse of claim 4, wherein the mouse further exhibits progressively impaired or reduced motor functions.

### Claim 6 (depends on 3)

The transgenic mouse of claim 3, whose hippocampus and cortex, but not cerebellum and spinal cord, exhibit an increased amount of TDP-43 protein.

### Claim 7 (depends on 6)

The transgenic mouse of claim 6, which is either a homozygous or hemizygous transgenic mouse, wherein the homozygous mouse and hemizygous transgenic mouse exhibit similar levels of TDP-43 protein.

### Claim 8 (depends on 1)

The transgenic mouse of claim 1, whose hippocampus and cortex, but not cerebellum and spinal cord, exhibit at least a 2-fold increase in the level of TDP-43 protein.

### Claim 9 (depends on 3)

The transgenic mouse of claim 3, whose hippocampus and cortex exhibit an altered level of a protein and/or a neurotransmitter member selected from the group consisting of phosphorylated extracellular signal-regulated kinase (pERK), phosphorylated cAMP-response element-binding Protein (pCREB), glutamic acid decarboxylase 67 (GAD67), glial fibrillary acidic protein (GFAP), gamma-aminobutyric acid (GABA) and capsase-3.

### Claim 10 (depends on 3)

The transgenic mouse of claim 3, wherein the brain of the mouse exhibits poly-ubiquitinated TDP-43.

### Claim 11 (depends on 10)

The transgenic mouse of claim 10, wherein the amount of poly-ubiquitinated TDP-43 in the brain of the mouse increases with age.

### Claim 12 (depends on 3)

The transgenic mouse of claim 3, wherein the brain neurons of the mouse exhibits cytoplasmic TDP-43 inclusion bodies.

### Claim 13 (depends on 12)

The transgenic mouse of claim 12, wherein the cytoplasmic TDP-43 inclusion bodies are ubiquitin positive.

### Claim 14 (depends on 3)

The transgenic mouse of claim 3, wherein the mouse exhibits brain atrophy, neuronal loss and learning memory loss.

### Claim 15 (depends on 1)

A method for evaluating potential therapeutic effects of a compound for treating, preventing and/or inhibiting frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) in a mammal, comprising the steps of:
(a) administering the compound to a transgenic mouse according to claim 1; and
(b) determining the potential therapeutic effects of the compound on the transgenic mouse by identifying improvement in learning and memory behavior and/or motor function of the tansgeinc mouse.

### Claim 16 (depends on 1)

A method for identifying a candidate agent for treating, preventing and/or inhibiting FTLD-U, comprising the steps of:
a) measuring the level of TDP-43 expression in the transgenic mouse of claim 1;
b) administering the agent to the transgenic mouse; and
c) measuring the level of TDP-43 expression in the transgenic mouse;
wherein a decrease in the level of TDP-43 expression after treatment with the agent identifies the agent as a candidate agent for treating, preventing and/or inhibiting FTLD-U.

### Claim 17 (depends on 1)

A neuronal cell isolated or derived from a transgenic mouse according to claim 1, the neuronal cell expressing an increased level of TDP-43-mRNA as compared to a neuronal cell isolated or derived from a non-transgenic mouse.

### Claim 18 (depends on 17)

The neuronal cell of claim 17, wherein the neuronal cell exhibits TDP-43 protein inclusion bodies in the cytosol thereof.

### Claim 19

A neuronal cell comprising a transgene operably linked to a neuronal specific promoter effective for an increased expression of the transgene in the neuronal cell, the transgene comprising a nucleotide sequence encoding TAR DNA-binding protein 43 (TDP-43), wherein the neuronal cell exhibits TDP-43 protein inclusion bodies in the cytosol thereof.

### Claim 20 (depends on 19)

The neuronal cell of claim 19, wherein the neuronal specific promoter is selected from the group consisting of Ca2+/calmodulin-dependent kinaseIIα (CaMKIIα) promoter, neuron-specific enolase (NSE) promoter and motor neuron-specific promoter.
